Bank of New York Mellon Corp Buys New Shares in CeriBell (NASDAQ:CBLL)

Bank of New York Mellon Corp purchased a new position in shares of CeriBell (NASDAQ:CBLL) in the fourth quarter, according to its most recent filing with the SEC. The firm purchased 24,274 shares of the company’s stock, valued at approximately $628,000.

Separately, Rhumbline Advisers acquired a new stake in CeriBell during the fourth quarter worth approximately $320,000.

CeriBell Stock Down 2.9 %

NASDAQ CBLL opened at $19.57 on Thursday. CeriBell has a 52 week low of $18.69 and a 52 week high of $32.75. The firm’s 50 day moving average price is $22.37.

CeriBell (NASDAQ:CBLL) last announced its quarterly earnings results on Tuesday, February 25th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.08). The business had revenue of $18.53 million for the quarter, compared to analyst estimates of $17.55 million. On average, equities analysts anticipate that CeriBell will post -2.46 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the company. Canaccord Genuity Group reissued a “buy” rating and issued a $33.00 price target on shares of CeriBell in a research note on Wednesday, February 26th. TD Cowen boosted their target price on shares of CeriBell from $31.00 to $36.00 and gave the company a “buy” rating in a research report on Monday, December 9th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $32.60.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.